Navigation Links
Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting

on Cancer Center; Abstract #3547; June 2, 2007; 2:00-6:00pm; McCormick Place Convention Center, S102a

MGCD0103

Oral Presentation: A Phase II Study of a Novel Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor in Patients With Relapsed or Refractory Hodgkin's lymphoma -- A. Younes, MD, MD Anderson Cancer Center; Abstract #8000; June 2, 2007; 3:00-3:15pm; McCormick Convention Center, E450b

Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) -- G. Garcia-Manero, MD, MD Anderson Cancer Center; Abstract #7062; June 2, 2007; 8:00am-12:00pm; McCormick Convention Center, S Hall A2

A Phase I study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS) -- J. Lancet, MD, H. Lee Moffitt Cancer Center; Abstract #2516; June 4, 2007; 2:00-6:00pm; McCormick Convention Center, S102a

Thalidomide

Oral Presentation: Melphalan-Prednisone-Thalidomide (MP-T) is also superior to Melphalan-Prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo-controlled IFM 01-01 trial -- C. Hulin, IFM, France; Abstract #8001; June 4, 2007; 7:30-7:45am; McCormick Place Convention Center, E Arie Crown Theater

Oral Presentation: Long-term responses to thalidomide and rituximab in Waldenstrom's macroglobulinemia -- J. Soumera; Abstract #8017; June 3, 2007; 1:00-1:15pm; McCormick Place Convention Center, E354b

Oral Presentation: Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM) -- P. Sonneveld; Abstract #8023; June 3, 2007; 3:00-3:15pm; McCormick Place Convention Center, E354b

An analysis of erythro
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:5/22/2013)... 22, 2013 The new 13-valent pneumococcal conjugate ... previous version used prior to 2010, the 7-valent pneumococcal ... published today in Vaccine. The U.S. Food ... 2010 after a series of trials. These trials found ... pneumococcal types than the previously used PCV7, did not ...
(Date:5/22/2013)... May 22, 2013  Healthcare providers are ... content management (ECM) solution, for a ... System .  These organizations identified enterprise content ... will use OnBase to optimize their Meditech ... (Logo:  http://photos.prnewswire.com/prnh/20090130/65710LOGO  ) ...
(Date:5/22/2013)... , 22. Mai 2013 Kepner-Tregoe ... Beratung, gab heute bekannt, dass der Veteran ... , zum Hauptgeschäftsführer ernannt wurde. Geraghty,s ... Industriebereich wo er zahlreiche Führungspositionen bei Fertigungsunternehmen ... Baxter an, der als Kepner-Tregoe Hauptgeschäftsführer gedient ...
Breaking Medicine Technology:Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 2Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 3Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 2Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 3
... MORRISTOWN, N.J. , May 4 Sagent Pharmaceuticals, ... leading global generic pharmaceutical manufacturer, have launched an exclusive collaboration to ... the United States . , ... Under the agreement, Actavis will develop, obtain U.S. ...
... Provides Significantly Better Pain Relief Compared to Component Doses; Study Goals and ... , , ... 4 QRxPharma (ASX: QRX and OTCQX: QRXPY) announced ... IR, an immediate-release Dual-Opioid pain therapy.  Required for New Drug Application (NDA) ...
Cached Medicine Technology:Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products 2Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products 3QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain 2QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain 3QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain 4QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain 5
(Date:5/22/2013)... May 22, 2013 DePuy Pinnacle ... DePuy Pinnacle Hip Replacement System continue to move forward ... Bernstein Liebhard LLP reports. According to an Order ... to produce monitoring reports associated with a 2007 criminal ... device marketing practices. Plaintiffs maintained in their ...
(Date:5/22/2013)... 22, 2013 Today, Zane Benefits, Inc. ... Insurance Exchange . Zane Benefits, which provides comprehensive and ... the leader in defined contribution plans and ... Benefits’ website, beginning in 2014 as part of the ... and small businesses will become available through new state ...
(Date:5/22/2013)... that hospitals may be reaping enormous income for ... bloodstream infections contracted in their intensive care units. ... in the American Journal of Medical Quality ... who develops an avoidable central line-associated bloodstream infection ... for than a similar infection-free patient. Moreover, hospitals ...
(Date:5/22/2013)... 2013 Registered Dietitian and Founder of Tatalou ... Tatalou.com sharing a recipe for making energy bars at home. ... Bars ,” takes a recipe modified from one recently ... “Every day it gets more and more difficult to understand ... “The size of the nutrition label continues to grow and ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Unknown to the ... area at 30 mph. Minutes before it struck, the ... the nearing threat. This gave them time to reach safety ... Data is proud to provide a product that will ... A Wheelock SAFEPATH® SP40S Emergency Evacuation System provides ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 3Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Telcom & Data Introduces Wheelock SAFEPATH® SP40S Emergency Evacuation System, An Effective Office Tool to Protect Employees from Severe Weather Threats 2
... Feb. 20 /Xinhua-PRNewswire/ -- Venture Global Limited,unveils the ... pollution. With VEGO Power Blocker, cellphone users could ... Be Protected, VEGO Power Blocker Kills the Invisible ... VEGO Power Blocker is a piece of ultra-thinned ...
... first scientific evidence that deadly emerging diseases have ... the outbreaks main sources. They say new diseases ... the greatest threat to humans. Expansion of humans ... with wildlife are the reason, they say. Meanwhile, ...
... Anti-bleeding agent Trasylol tied to increased death, complications, studies ... new studies confirm an increased incidence of death and ... used to reduce bleeding during coronary artery bypass surgeries. ... over both the short- and long-term. , Trasylol,s German ...
... , , WEDNESDAY, Feb. 20 (HealthDay News) -- The time of day ... the difference between life and death. , Two new studies find ... weekends are more likely to die in the hospital than those ... acceptable, one researcher said. "We should not be treating patients ...
... heart disease had no ... risk factors, BALTIMORE, Feb. 20 In an effort to ... Foundation will,hold its annual Women,s Heart Health Fair on Tues., Feb. ... Mayor Sheila,Dixon has granted non-essential female workers two hours leave that ...
... put an end to toothaches, PHILADELPHIA, Feb. ... model, based in Philadelphia, announced that it is,expanding ... offering licensing,opportunities to qualifying dental practices, worldwide. This ... in advancing,affordable dental/health care available everywhere, to all., ...
Cached Medicine News:Health News:Venture Global Limited Introduces an Innovative Anti-Cellphone Radiation Sticker Named 'VEGO Power Blocker' 2Health News:Scientists make first map of emerging-disease hotpsots 2Health News:Scientists make first map of emerging-disease hotpsots 3Health News:More Evidence of Danger From Heart Surgery Drug 2Health News:More Evidence of Danger From Heart Surgery Drug 3Health News:In-Hospital Stroke Deaths Rise on Nights, Weekends 2Health News:In-Hospital Stroke Deaths Rise on Nights, Weekends 3Health News:Free Health Screenings Aim to Identify Risk of Heart Disease in Women 2Health News:Emergency Dentist 24/7(TM) Announces Worldwide Licensing Program 2
Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests....
For use with catalog #0540....
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Antigenic Free Protein S, ELISA Method...
Medicine Products: